
    
      RENACALL is a prospective intermediate care study whose main aim is to evaluate the impact of
      a therapy management platform on the management of patients suffering from
      advanced/metastatic renal cell carcinoma and receiving first line treatment with Sutent®.

      100 mRCC patients treated receiving first line Sutent® treatment shall be included in the
      study, and shall benefit both from conventional follow-up and from additional therapy
      management platform-based follow-up. Platform follow-up shall consist in regular phone calls
      to accompany patients in their real life home management of their treatment with sunitinib
      (prevention, advice and guidance of patients towards options)..
    
  